Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
VTYX Ventyx Biosciences
40.920-1.540-3.63%
Close
02/08 16:00 ET
40.9200.0000.00%
Post Mkt Price 02/08 16:00 ET
High
42.590
Open
41.980
Turnover
23.14M
Low
40.620
Pre Close
42.460
Volume
562.95K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Ventyx Biosciences (NASDAQ:VTYX) Sets New 1-Year High at $44.30
Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $44.30 and last traded at $44.30, with a volume of 4297 sha
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) Is a Great Choice
Canaccord Genuity Group Increases Ventyx Biosciences (NASDAQ:VTYX) Price Target to $54.00
Ventyx Biosciences (NASDAQ:VTYX – Get Rating) had its target price boosted by Canaccord Genuity Group from $35.00 to $54.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a
Ventyx Biosciences Price Target Raised to $54.00/Share From $35.00 by Canaccord Genuity
Ventyx Biosciences Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Ventyx Biosciences, Raises Price Target to $54
Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences with a Buy and raises the price target from $35 to $54.
Ventyx Biosciences (VTYX) Gets a Buy From H.C. Wainwright
DekaBank Deutsche Girozentrale Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)
DekaBank Deutsche Girozentrale purchased a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure w
Evercore ISI Increases Ventyx Biosciences (NASDAQ:VTYX) Price Target to $65.00
Ventyx Biosciences (NASDAQ:VTYX – Get Rating) had its price objective raised by research analysts at Evercore ISI from $50.00 to $65.00 in a report issued on Thursday, The Fly reports. Evercore ISI'
Ventyx Biosciences Price Target Raised to $60.00/Share From $55.00 by Oppenheimer
Company Overview
More
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.
CEO： Dr. Raju S. Mohan, PhD
Market： NASDAQ
Listing Date： 10/21/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet